Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 007002108 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Orbimed Advisors LLC
13D/A
Amendment 9
|
8.8% |
4/10/2026
Event 4/8/2026
|
|
| Orbimed Advisors LLC | 8.8% | ||
| Orbimed Capital GP VI LLC | 2.9% | ||
| Orbimed Capital GP V LLC | 5.9% | ||
| OrbiMed Genesis GP LLC | 0% | ||
| Orbimed Advisors Israel II Ltd | 0% | ||
| Orbimed Israel GP II, L.P. | 0% | ||
| Orbimed Israel GP Ltd. | 0% | ||
| Orbimed Israel Biofund GP Limited Partnership | 0% | ||
|
Orbimed Advisors LLC
13D/A
Amendment 8
|
9.6% |
10/10/2025
Event 10/8/2025
|
|
| Orbimed Advisors LLC | 9.6% | ||
| Orbimed Capital GP VI LLC | 2.9% | ||
| Orbimed Capital GP V LLC | 5.9% | ||
| OrbiMed Genesis GP LLC | 0.8% | ||
| Orbimed Advisors Israel II Ltd | 0.4% | ||
| Orbimed Israel GP II, L.P. | 0.4% | ||
| Orbimed Israel GP Ltd. | 0.7% | ||
| Orbimed Israel Biofund GP Limited Partnership | 0.7% | ||
|
Tang Capital Management LLC
13G/A
Amendment 3
|
9.9% |
5/15/2025
Event 3/31/2025
|
|
| Tang Capital Management, LLC | 9.9% | ||
| Kevin Tang | 9.9% | ||
| Tang Capital Partners, LP | 5.7% | ||
| Tang Capital Partners International, LP | 4.2% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q1 | 1 | 60.5 k | $412 k |
| 2025 Q4 | 1 | 60.5 k | $510 k |
| 2025 Q3 | 55 | 51.4 M | $41.6 M |
| 2025 Q2 | 52 | 51.6 M | $31.5 M |
| 2025 Q1 | 59 | 55.9 M | $42.0 M |
| 2024 Q4 | 68 | 57.6 M | $55.4 M |
| 2024 Q3 | 68 | 57.2 M | $82.4 M |
| 2024 Q2 | 92 | 65.1 M | $78.8 M |
| 2024 Q1 | 105 | 83.3 M | $196 M |
| 2023 Q4 | 83 | 36.2 M | $68.4 M |
| 2023 Q3 | 87 | 35.7 M | $48.9 M |
| 2023 Q2 | 101 | 37.2 M | $90.4 M |
| 2023 Q1 | 113 | 40.3 M | $231 M |
| 2022 Q4 | 108 | 44.4 M | $397 M |
| 2022 Q3 | 109 | 41.7 M | $592 M |
| 2022 Q2 | 108 | 38.0 M | $556 M |
| 2022 Q1 | 95 | 33.1 M | $661 M |
| 2021 Q4 | 89 | 30.4 M | $532 M |
| 2021 Q3 | 59 | 19.9 M | $156 M |
| 2021 Q2 | 67 | 21.2 M | $218 M |
| 2021 Q1 | 55 | 20.4 M | $266 M |
| 2020 Q4 | 46 | 9.56 M | $134 M |
| 2020 Q3 | 35 | 9.05 M | $108 M |